Study of the Safety and Efficacy of the Hydroxychloroquine Protocol against COVID-19 in Algeria: Experience of the Gynaecology Department of the EHU Oran

Abstract

In Algeria, the Scientific Council of the Ministry of Health has decided on the hydroxychloroquine protocol for the treatment of patients with COVID-19, as the hydroxychloroquine molecule has not been the subject of a randomized clinical trial and the therapeutic evidence remains uncertain. The safety of hydroxychloroquine remains dependent on a study to secure and evaluate the efficacy of this protocol in the management of COVID- 19 infection. This is a prospective study of 55 patients with COVID-19 hospitalized in the gynaecology department at EHU Oran for a period of one month and confirmed by RT-PCR or thoracoabdominal CT scan. The safety indicator and therapeutic evaluation were based on active reporting of protocol adverse events. In conclusion, the COVID-19 therapeutic protocol is not devoid of adverse effects, even though it brings a benefit, whereas during our study some patients who did not benefit from the protocol showed the same remission rate.